Clinical trial
Open access
Aug 2026
Neoadjuvant anti-HER2 antibody-drug conjugate SHR-A1811 in Hormone Receptor-positive, HER2-low Breast Cancer: A Phase 2 Clinical Trial (HELEN-015)
A phase II interventional clinical trial evaluating the anti-HER2 ADC SHR-A1811 as neoadjuvant monotherapy in patients with HR’+ HER2-low breast cancer, suggesting a potential alternative neoadjuvant option for HR’+ /HER2-low breast cancer.
D. Jiao, Jiu-Jun Zhu, Xian-Fu Sun et al.
· Nature Communications · 0 citations